Design and synthesis of novel inhibitors of the anti-infective target IspE
Due to the current antimicrobial resistance crisis, addressing underexplored targets to afford anti-infective compounds with novel modes of action is urgently needed. Antimicrobial resistance not only poses a threat to public heal...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
CTQ2017-82222-R
DESCUBRIMIENTO Y DESARROLLO DE NUEVOS COMPUESTOS QUIMICOS Y...
171K€
Cerrado
QTB4AMR
Utilizing an innovative chemical platform to defeat antimicr...
71K€
Cerrado
SPACE4AMPS
Chemical Space for Antimicrobials on a Peptide Basis
2M€
Cerrado
BLISS
Beta-Lactamase Inhibitors Synthesised through in Situ click...
Cerrado
RTI2018-102040-B-I00
PROPIEDADES ANTIMICROBIANAS DE NUEVOS COMPLEJOS ORGANOMETALI...
43K€
Cerrado
SEQUENCING
Reaction Sequencing A concise asymmetric approach to the an...
169K€
Cerrado
Información proyecto KpIspE
Duración del proyecto: 26 meses
Fecha Inicio: 2023-06-21
Fecha Fin: 2025-08-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Due to the current antimicrobial resistance crisis, addressing underexplored targets to afford anti-infective compounds with novel modes of action is urgently needed. Antimicrobial resistance not only poses a threat to public health, but is a substantial cost burden on the healthcare system. This proposal focuses on the design and synthesis of novel inhibitors of the target 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE). IspE catalyzes the fourth step in the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway which is essential for medically relevant pathogens (e.g., Enterobacter coli, Klebsiella pneumoniae, Mycobacterium tuberculosis and Pseudomonas aeruginosa) but entirely absent in humans, making this enzyme a promising drug target. We will initially explore drug fragments through the screening of carefully constructed fragment libraries, followed by hit-to-lead optimization for promising compounds. Target confirmation will be performed using a biologically active small-molecule photo-crosslinking probe and a crystal structure of IspE obtained in complex with a promising inhibitor.
The investigation of potential for therapeutic intervention via inhibition of IspE will result in several potent inhibitors, enhancing the knowledge of this underexplored enzyme target and opening up access for further exploration of potent inhibitors. This research will greatly contribute to the discovery of novel anti-infective agents, leading to decreased morbidity and mortality in patients, economical benefits for the health care system in the European Union as well as globally.